

## ExpreS<sup>2</sup>ion will participate in key industry and investor events

**Hørsholm, Denmark, September 20, 2022** – **ExpreS<sup>2</sup>ion Biotech Holding AB's affiliate ExpreS<sup>2</sup>ion Biotechnologies ApS ("ExpreS<sup>2</sup>ion") will participate and hold presentations at key industry and investor events in the coming month. These include PIVAC-22, a forum covering the most recent advances in cancer immunotherapy (September 26-28) and Aktiedagen Lund (September 26).**

By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS<sup>2</sup> technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company's [website](#).

### **Progress in Vaccination Against Cancer (PIVAC-22), September 26-28, Torino, Italy**

Meet ExpreS<sup>2</sup>ion's VP of Preclinical Development, Dr. Mette Thorn, and hear the company's preclinical development partners from the University of Bologna present on "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine," in a forum covering the most recent advances in the field of cancer immunotherapy. More information and registration can be found on the [PIVAC-22 website](#).

### **Aktiedagen Lund, September 26 at 11:00 CET, Virtual**

Join CEO of ExpreS<sup>2</sup>ion Biotechnologies Bent U. Frandsen for a live update at Aktiedagen in Lund. You can stream the event live or on demand via Aktiespararnas [YouTube Channel](#) or at [Aktiespararna.se/tv/live](#).

### **Certified Adviser**

Svensk Kapitalmarknadsgranskning AB  
Telefon: +46 11 32 30 732  
E-post: [ca@skmg.se](mailto:ca@skmg.se)

### **For further information about ExpreS<sup>2</sup>ion Biotech Holding AB, please contact:**

Bent U. Frandsen, CEO  
Telephone: +45 4256 6869  
E-mail: [buf@expres2ionbio.com](mailto:buf@expres2ionbio.com)

Keith Alexander, CFO  
Telephone: +45 5131 8147  
E-mail: [ka@expres2ionbio.com](mailto:ka@expres2ionbio.com)

### **About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. ExpreS<sup>2</sup>ion has developed a unique technology platform, ExpreS<sup>2</sup>, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS<sup>2</sup> is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS<sup>2</sup>ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS<sup>2</sup>ion owns 34%. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com).